17266-30-7 Usage
Uses
Used in Pharmaceutical Industry:
5-Chlorobenzo[b]thiophene-3-acetic acid is used as a pharmaceutical compound for its potential anti-inflammatory and analgesic properties. It is being studied for its efficacy in treating conditions such as osteoarthritis and rheumatoid arthritis, where its ability to reduce inflammation and alleviate pain could provide significant benefits to patients.
Used in Medicinal Chemistry and Drug Development:
In the field of medicinal chemistry, 5-chlorobenzo[b]thiophene-3-acetic acid is of interest due to its potential as a lead compound in the development of new drugs. Its synthesis and characterization are crucial steps in understanding its properties and exploring its therapeutic potential. Researchers are investigating its mechanism of action and optimizing its structure to enhance its efficacy and safety for various medical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 17266-30-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,2,6 and 6 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 17266-30:
(7*1)+(6*7)+(5*2)+(4*6)+(3*6)+(2*3)+(1*0)=107
107 % 10 = 7
So 17266-30-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H7ClO2S/c11-7-1-2-9-8(4-7)6(5-14-9)3-10(12)13/h1-2,4-5H,3H2,(H,12,13)
17266-30-7Relevant academic research and scientific papers
Orally absorbable cephalosporine antibiotics. 1. Structure-activity relationships of benzothienyl- and naphthylglycine derivatives of 7-aminodeacetoxycephalosporanic acid
Kukolja,Draheim,Pfeil,et al.
, p. 1886 - 1896 (2007/10/02)
A structure-activity relationship study of a number of orally absorbed cephalosporins together with their syntheses is described. These new cephalosporins are benzothienyl- and naphthylglycine derivatives of 7-aminodeacetoxycephalosporanic acid. Several different synthetic methods for the glycine side chains, their protection, and the final acylations are reported. Several of these analogues were more active than cephalexin both in vitro and r538w2 =(R)-7-(3-Benzothienylglycylamido)-3-methyl-3-cephem-4-carb oxylic in vivo against commonly encountered Gram-positive bacteria. (R)7-(3-Benzothienylglycylamido)-3-methyl-3-cephem-4-carboxylic acid has emerged as a potent antibacterial agent and is currently undergoing preclinical evaluation.
